Skip to main content

Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study.

Publication ,  Journal Article
Zeng, H; Cao, M; Xia, C; Wang, D; Chen, K; Zhu, Z; Fu, R; Zhang, S; Zhou, J; Wang, H; Qi, X; Dai, S; Chen, Y; Sun, Z; Ding, H; Li, Q ...
Published in: Nature cancer
September 2023

Current guidelines recommend hepatocellular carcinoma (HCC) surveillance for at-risk individuals, including individuals with hepatitis B virus infection. However, the performance and survival benefits of annual screening have not been evaluated through multicenter prospective studies in a Chinese population. Between 2017 and 2021, we included 14,426 participants with hepatitis B surface antigen seropositivity in an annual HCC screening study in China using a multicenter prospective design with ultrasonography and serum alpha-fetoprotein. After four rounds of screening and follow-up, the adjusted hazard ratios of death after correction for lead-time and length-time biases for screen-detected cancers at the prevalent and incident rounds were 0.74 (95% confidence interval = 0.60-0.91) and 0.52 (95% confidence interval = 0.40-0.68), respectively. A meta-analysis demonstrated that HCC screening was associated with improved survival after adjusting for lead-time bias. Our findings highlight the 'real-world' feasibility and effectiveness of annual HCC screening in community settings for the early detection of HCC and to improve survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nature cancer

DOI

EISSN

2662-1347

ISSN

2662-1347

Publication Date

September 2023

Volume

4

Issue

9

Start / End Page

1382 / 1394

Related Subject Headings

  • Prospective Studies
  • Liver Neoplasms
  • Humans
  • Hepatitis B Surface Antigens
  • China
  • Carcinoma, Hepatocellular
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zeng, H., Cao, M., Xia, C., Wang, D., Chen, K., Zhu, Z., … Chen, W. (2023). Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study. Nature Cancer, 4(9), 1382–1394. https://doi.org/10.1038/s43018-023-00618-8
Zeng, Hongmei, Maomao Cao, Changfa Xia, Dongmei Wang, Kun Chen, Zheng Zhu, Ruiying Fu, et al. “Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study.Nature Cancer 4, no. 9 (September 2023): 1382–94. https://doi.org/10.1038/s43018-023-00618-8.
Zeng, Hongmei, et al. “Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study.Nature Cancer, vol. 4, no. 9, Sept. 2023, pp. 1382–94. Epmc, doi:10.1038/s43018-023-00618-8.
Zeng H, Cao M, Xia C, Wang D, Chen K, Zhu Z, Fu R, Zhang S, Zhou J, Wang H, Qi X, Dai S, Chen Y, Sun Z, Ding H, Li Q, Zhao H, Zhang X, Morze J, Ji JS, Sun F, Yu X, Qu C, Chen W. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study. Nature cancer. 2023 Sep;4(9):1382–1394.

Published In

Nature cancer

DOI

EISSN

2662-1347

ISSN

2662-1347

Publication Date

September 2023

Volume

4

Issue

9

Start / End Page

1382 / 1394

Related Subject Headings

  • Prospective Studies
  • Liver Neoplasms
  • Humans
  • Hepatitis B Surface Antigens
  • China
  • Carcinoma, Hepatocellular
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology